You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-PD-L1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Advanced Solid Tumor Trial (HLX43)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Oct 30, 2023

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

Contribution of Fractional Exhaled Nitric Oxide asPrognostic

Not yet recruiting
  • Metastatic Non-small Cell Lung Cancer
  • Measurement of FeNO
  • Dijon, France
    Chu Dijon Bourgogne
Aug 8, 2023

Solid Carcinoma Trial (fecal microbiota transplantation with Nivolumab)

Not yet recruiting
  • Solid Carcinoma
  • fecal microbiota transplantation with Nivolumab
  • (no location specified)
Sep 14, 2022

Unresectable Hepatocellular Carcinoma Trial (Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib)

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • Huaier granule
  • +3 more
  • (no location specified)
Dec 20, 2022

Advanced Solid Tumours Trial (PM1021, PM8001)

Not yet recruiting
  • Advanced Solid Tumours
  • PM1021, PM8001
  • (no location specified)
Sep 12, 2022

Immunotherapy in Upper Tract Urothelial Carcinoma

Not yet recruiting
  • Urothelial Carcinoma
  • Evaluation of anti-PD-(L)1 immunotherapy efficacy
  • (no location specified)
Oct 27, 2023

HIV Trial (ASC22 group)

Not yet recruiting
  • HIV Infections
  • ASC22 group
  • (no location specified)
Mar 4, 2022

Advanced Urothelial Carcinoma Trial in Beijing (anti-PD-L1 antibody, albumin bound paclitaxel)

Active, not recruiting
  • Advanced Urothelial Carcinoma
  • anti-PD-L1 antibody
  • albumin bound paclitaxel
  • Beijing, Beijing, China
    Beijing Tumor Hospital
Jan 20, 2022

Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Recruiting
  • Graft Rejection
  • +3 more
  • Immune checkpoint inhibitor
  • Guangzhou, Guangdong, China
    Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
Jun 21, 2023

Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Helsinki (TILT-123, Avelumab)

Recruiting
  • Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Helsinki, Finland
    Docrates Cancer Center
Jul 12, 2022

SCLC Trial (PM8002, Platinum, Atezolizumab)

Not yet recruiting
  • SCLC
  • (no location specified)
May 4, 2023

Small Cell Lung Cancer Recurrent Trial in Goyang-si (Atezolizumab)

Recruiting
  • Small Cell Lung Cancer Recurrent
  • Goyang-si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Head Neck Cancer, Head and Neck Tumors Trial run by the NCI (M7824, N803, TriAd vaccine)

Active, not recruiting
  • Head and Neck Cancer
  • Head and Neck Neoplasms
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

Extensive Stage Small Cell Lung Cancer Trial in Shanghai (recombinant anti-PD-L1 mAb injection combined with carboplatin and

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
May 9, 2022

Solid Tumors, Adult Trial in Kaunas (NECVAX-NEO1)

Recruiting
  • Solid Tumors, Adult
  • NECVAX-NEO1
  • Kaunas, Lithuania
    Elona Juozaityte
May 16, 2022

Head Neck Cancer Trial in Boston (Oral Decitabine, Durvalumab)

Active, not recruiting
  • Head and Neck Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 30, 2022

Cancer Trial in United States (SRK-181, anti-PD-(L)1 antibody therapy)

Recruiting
  • Cancer
  • SRK-181
  • anti-PD-(L)1 antibody therapy
  • Fullerton, California
  • +13 more
Jan 6, 2023

Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital Fudan university
Jan 31, 2023

Malignant Tumors of Digestive Organs, Colorectal Cancer, Colon Cancer Trial in Houston (Durvalumab, Trametinib)

Completed
  • Malignant Neoplasms of Digestive Organs
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
May 23, 2022

Advanced or Metastatic NSCLC Trial in Moscow, Saint Petersburg, St. Petersburg (Ceralasertib, Durvalumab)

Recruiting
  • Advanced or Metastatic NSCLC
  • Moscow, Russian Federation
  • +7 more
Jul 4, 2023

Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation

Completed
  • Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
  • Anti-PD-1 or anti-PD-L1
  • Montpellier, France
    UH Montpellier
Dec 22, 2021

Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck Trial in New Haven, Atlanta, Portland

Recruiting
  • Solid Tumor
  • +3 more
  • New Haven, Connecticut
  • +2 more
Aug 1, 2022

SCLC,Extensive Stage, SLFN11-positive Trial in Worldwide (Niraparib)

Not yet recruiting
  • SCLC,Extensive Stage
  • SLFN11-positive
  • Angers, France
  • +19 more
Jan 30, 2023